ADBiotech Co

ADBiotech Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of ADBiotech Co (179530.KQ) as of Oct 15, 2026 is -7.23 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -38.19 % — a change of -81.06% (higher).

EBIT/Assets

-7.23 %

YoY

-81.06%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of ADBiotech Co is 2025 -7.23 % . Operating Income to Assets Ratio (EBIT/Assets) of ADBiotech Co was 2024 -38.19 % . It decreases by -81.06% higher compared to the previous year.

The ADBiotech Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-33.70 KRW
Jan 1, 2019
2.24 KRW
Jan 1, 2020
-5.29 KRW
Jan 1, 2021
-10.93 KRW
Jan 1, 2022
-15.92 KRW
Jan 1, 2023
-26.29 KRW
Jan 1, 2024
-38.19 KRW
Jan 1, 2025
-7.23 KRW
The ADBiotech Co EBIT/Assets history
YEAREBIT/AssetsYoY
-7.23 %-81.06%
-38.19 %+45.29%
-26.29 %+65.10%
-15.92 %+45.70%
-10.93 %+106.65%
-5.29 %-335.85%
2.24 %-106.65%
-33.70 %-1,384.00%
2.62 %-120.05%
-13.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ADBiotech Co Stock analysis

What does ADBiotech Co do? ADbiotech Co., Ltd. is a South Korean enterprise operating within the health care sector, specifically categorized under the pharmaceuticals industry. The company is headquartered in Chuncheon, located in the Gangwon-Do province, and maintains a digital presence at http://www.adbiotech.com/. ADBiotech went public on December 24, 2019, marking its entry into the stock market with the ticker symbol 179530.KQ and the International Securities Identification Number KR7179530001. The firm is primarily engaged in the research and development of chemical products designed for use in pharmaceuticals, stockbreeding, and fisheries. Its business operations are structured around two distinct segments: Veterinary Medicine and Supplementary Feed. The Veterinary Medicine segment focuses on the manufacture and sale of a diverse range of animal health products. This includes antibiotics, which are critical for treating bacterial infections in livestock and pets. The company also produces anticoccidial agents, which are used to prevent and treat coccidiosis, a common parasitic disease in animals. Additionally, the segment covers antimicrobial agents and nervous system agents, addressing various neurological and microbial health issues in veterinary patients. Synthetic antibacterial agents are also part of this portfolio, providing effective solutions for bacterial control in animal health management. The Supplementary Feed segment complements the veterinary offerings by engaging in the manufacture and sale of functional supplementary feeds. These products are designed to enhance the nutritional value of animal diets, supporting overall health and productivity in stockbreeding operations. By offering functional supplementary feeds and other related products, ADBiotech aims to provide comprehensive solutions that address both medical and nutritional needs in the agricultural and veterinary sectors. The company's dual-segment approach allows it to cater to a broad spectrum of customers, from veterinary clinics and animal hospitals to large-scale agricultural operations. Through its focus on research and development, ADBiotech seeks to innovate and improve the quality of its chemical products, ensuring they meet the evolving demands of the pharmaceutical and agricultural industries. As a publicly traded company, ADBiotech is subject to regulatory oversight and reporting requirements, which help maintain transparency and accountability for its investors and stakeholders. The company's presence in Chuncheon, a region known for its agricultural and industrial activities, positions it well to serve the local and national markets while potentially expanding its reach internationally. Overall, ADBiotech Co., Ltd. plays a significant role in the South Korean health care and pharmaceutical landscape, contributing to the advancement of veterinary medicine and animal nutrition through its specialized product offerings and commitment to research and development. ADBiotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ADBiotech Co stock

Operating Income to Assets Ratio (EBIT/Assets) of ADBiotech Co is -7.23 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of ADBiotech Co changed from -38.19 % to -7.23 %, representing a -81.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) ADBiotech Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s ADBiotech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — ADBiotech Co

All Key Metrics — ADBiotech Co